Table 1

Features of included patients. VL: viral load. HAART: highly active antiretroviral therapy
Variable Number of patients (percentage), except where specified
Median age (range) 37 years (23–63)
Male gender 45 (68)
Risk category
 Injection drug users 28(42)
 Men who have sex with men 16 (24)
 Heterosexual 22 (34)
Toxic habits
Current smoking 46 (69)
Alcholism 22 (33)
Methadone Maintenance Treatment 20 (30)
Median time since diagnosis of HIV infection (range) 10 years (2–16)
CDC category
 A 54 (82)
 B 6 (9)
 C 6 (9)
Number of previous antiretroviral regimens
 1 13 (20)
 2 16 (24)
 3 or more 37 (56)
Median time on HAART before interruption (range) 284 weeks (60–512)
Adherence <80% to any previous antiretroviral therapy 20 (30)
Previous virologic failure with any antiretroviral regimen
 No 53 (81)
 Yes 13 (19)
HCV coinfection 33 (50)
HBV coinfection 2 (3)
Median HIV-1 VL at diagnosis (range) 23.750 copies/mL (100–1.511.000)
Median nadir CD4+ cell count (range) 252 cells/μL (50–552)
Main reason for the interruption of HAART
 Proposed by physician 33 (50)
 Intolerance to current regimen 20 (30,3)
 Decision of the patient 10 (15,2)
 Problems for an appropriate adherence 3 (4,5)
Median CD4+ cell count at interruption (range) 745 (350–2132)

Machado et al.

Machado et al. BMC Research Notes 2012 5:578   doi:10.1186/1756-0500-5-578

Open Data